| 產(chǎn)品編號 | BIO0061SM |
| 英文名稱(chēng) | Anti-human B7-H1 / PD-L1 / CD274 (Avelumab Biosimilar) |
| 中文名稱(chēng) | |
| 抗體來(lái)源 | |
| 克隆類(lèi)型 | Monoclonal |
| 克 隆 號 | |
| 交叉反應 | Human,Mouse,Rat,Rabbit,Dog,Cynomolgus |
| 產(chǎn)品應用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 150 kDa |
| 檢測分子量 | |
| 性 狀 | Lyophilized |
| 亞 型 | Human IgG1 |
| 純化方法 | Protein A |
| 保存條件 | For long term storage, the produce should be stored at -20°C or lower. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Avelumab inhibited the tumor growth of MC38 on hLAG3 mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 32.6% at 1 mpk at D28.
Immobilized human PD-L1 FC at 2 ug/mL can bind Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (avelumab), EC50=0.03725 ug/mL.
The purity of Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (avelumab) is 98.22%, determined by SEC-HPLC.
Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (avelumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
